News | January 26, 2024
Laurus Labs inks JV agreement with KRKA, Slovenia
The registered capital of the newly founded company is € 50 million
The registered capital of the newly founded company is € 50 million
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Subscribe To Our Newsletter & Stay Updated
